Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma.

IF 3.5 3区 医学 Q2 ONCOLOGY
Frontiers in Oncology Pub Date : 2025-10-08 eCollection Date: 2025-01-01 DOI:10.3389/fonc.2025.1627281
Jing Mao, Hengzhi Zhang, Xingxia Yang, Yanjun Yao, Xu Sun, Qiang Yan
{"title":"Case Report: Efficacy of preoperative conversion therapy with lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy in an advanced hepatocellular carcinoma.","authors":"Jing Mao, Hengzhi Zhang, Xingxia Yang, Yanjun Yao, Xu Sun, Qiang Yan","doi":"10.3389/fonc.2025.1627281","DOIUrl":null,"url":null,"abstract":"<p><p>Advanced hepatocellular carcinoma (HCC) has a poor prognosis. Conversion therapy based on non-surgical local therapy and drug therapy is an effective treatment for unresectable HCC. We report a case of HCC with intrahepatic metastasis and multiple venous tumor thrombi. After nearly 4 months of conversion therapy with lenvatinib, toripalimab combined with hepatic arterial infusion chemotherapy (HAIC), the lesions were significantly reduced, the portal vein tumor thrombus resolved, and the alpha-fetoprotein (AFP) decreased to the normal range. This patient had no serious adverse events during treatment. After a comprehensive assessment of the patient's status, the patient eventually underwent curative surgical resection of the tumor and had a complete response. The successful experience of this case indicates that lenvatinib, toripalimab combined with HAIC has a good prospect as a conversion therapy for HCC with intrahepatic metastasis and multiple venous tumor thrombi.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1627281"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540137/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1627281","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Advanced hepatocellular carcinoma (HCC) has a poor prognosis. Conversion therapy based on non-surgical local therapy and drug therapy is an effective treatment for unresectable HCC. We report a case of HCC with intrahepatic metastasis and multiple venous tumor thrombi. After nearly 4 months of conversion therapy with lenvatinib, toripalimab combined with hepatic arterial infusion chemotherapy (HAIC), the lesions were significantly reduced, the portal vein tumor thrombus resolved, and the alpha-fetoprotein (AFP) decreased to the normal range. This patient had no serious adverse events during treatment. After a comprehensive assessment of the patient's status, the patient eventually underwent curative surgical resection of the tumor and had a complete response. The successful experience of this case indicates that lenvatinib, toripalimab combined with HAIC has a good prospect as a conversion therapy for HCC with intrahepatic metastasis and multiple venous tumor thrombi.

病例报告:lenvatinib, toripalimab和肝动脉输注化疗在晚期肝癌术前转换治疗的疗效。
晚期肝细胞癌(HCC)预后不良。以非手术局部治疗和药物治疗为基础的转化治疗是治疗不可切除肝癌的有效方法。我们报告一例肝癌合并肝内转移及多发性静脉肿瘤血栓。经lenvatinib、torpalimab联合肝动脉输注化疗(HAIC)治疗近4个月后,病变明显减少,门静脉肿瘤血栓溶解,甲胎蛋白(AFP)降至正常范围。该患者在治疗期间未发生严重不良事件。在对患者的病情进行全面评估后,患者最终接受了根治性手术切除肿瘤,并获得完全缓解。本病例的成功经验提示lenvatinib、toripalimab联合HAIC作为肝癌肝内转移及多发静脉肿瘤血栓的转化治疗具有良好的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Oncology
Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
6.20
自引率
10.60%
发文量
6641
审稿时长
14 weeks
期刊介绍: Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信